Neurology & CNS Licensing Deal Benchmarks 2026

The neurology and CNS licensing landscape in 2026 is characterized by renewed optimism following breakthroughs in Alzheimer's disease-modifying therapies and advances in blood-brain barrier penetration technologies. Alzheimer's Phase 2 deals lead in deal value at $3.5B median, while Parkinson's disease-modifying approaches command $3.1B. Pain therapeutics remain active at $2.1B with differentiated non-opioid mechanisms.

CNS deal structures are distinctively milestone-weighted compared to oncology, reflecting longer development timelines, complex clinical endpoints (cognitive scales, functional assessments), and historically lower approval rates. Disease-modifying therapies carry the highest milestone potential due to the extended pivotal trial durations (3-5 years) and the transformative commercial opportunity if endpoints are met.

Royalty rates in neurology licensing range from 12.8% to 20.5% at the base tier, with variations driven by BBB penetration data, disease-modification evidence, and competitive positioning. Key valuation differentiators unique to CNS include demonstrated brain penetration, biomarker-based patient selection, and pathway de-risking through novel clinical trial designs.